1. Home
  2. ANNX vs DGICB Comparison

ANNX vs DGICB Comparison

Compare ANNX & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.77

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

DGICB

Donegal Group Inc. Class B

N/A

Current Price

$22.90

Market Cap

889.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ANNX
DGICB
Founded
2011
1986
Country
United States
United States
Employees
N/A
851
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
812.7M
889.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ANNX
DGICB
Price
$5.77
$22.90
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$16.50
N/A
AVG Volume (30 Days)
4.4M
5.0K
Earning Date
05-11-2026
04-30-2026
Dividend Yield
N/A
3.34%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$2.26
Revenue Next Year
$16,320.74
N/A
P/E Ratio
N/A
$8.06
Revenue Growth
N/A
N/A
52 Week Low
$2.03
$13.84
52 Week High
$7.18
$24.00

Technical Indicators

Market Signals
Indicator
ANNX
DGICB
Relative Strength Index (RSI) 55.54 55.46
Support Level $4.75 $15.29
Resistance Level $5.89 $23.69
Average True Range (ATR) 0.42 1.61
MACD 0.08 0.21
Stochastic Oscillator 54.60 66.39

Price Performance

Historical Comparison
ANNX
DGICB

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About DGICB Donegal Group Inc. Class B

Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.

Share on Social Networks: